The healthcare market is poised to see some of the earliest benefits of nanotechnology. Over the next decade, it will be one of nanotech’s highest growth sectors. Targeted drug delivery therapies for the treatment of cancer is one of the most commonly cited nano-healthcare benefits. Cientifica’s report, Nanotechnology in Drug Delivery 2011, gives a comprehensive analysis and geographic breakdown of the current nanotechnology drug delivery market and its most relevant technologies. It also provides a forecast for the size of total addressable markets and percent share of those key technologies to 2021.

Some forecasts have predicted the nanotechnology market to reach close to a trillion dollars by 2015, presenting investors with unique opportunities. However, the market for applications of nanotechnology is complex, multidisciplinary and highly segmented. It is therefore essential to gain an understanding of which market sectors nanotechnology is likely to impact most profoundly in the near term.

Since we now know most (if not all) biological processes occur at the nanoscale, the application of life science principles – studying the causes of biological phenomena at the molecular level – means medical and biomedical research is increasingly using a bottom-up (rather than the top-down) approach. The low bioavailability resulting from traditional oral and intravenous drug delivery methods and the market forces at work in the pharmaceutical industry, where patents expire after a relatively short period of time unless a novel form of drug delivery is developed that will extend the patent, are two major forces that will fuel the growth of the nanotech drug delivery market. The third factor at play is a combination of improved global health and a correspondingly dramatic increase in the size of the global aging population.

This report provides insight into the possibilities of targeted nanotech drug delivery and its market potential over the next decade.

Market Scope

This report provides an in-depth presentation of recent developments in nanotech drug delivery (NDD) and provides market opportunities to 2021, for the largest economies in the Americas, Asia, Europe and the rest of the world. Two market analyses are presented;

•     The historical market growth for NDD between 2000-2010
•     Market forecast for NDD from 2011 to 2021

Both sets of data are segmented into market by geographical region (US$ millions, % share, and compound annual growth rates by country) for America; Asia, Europe, and Rest of the World (key economies only) and by technology type (US$ millions, percent share and compound annual growth rate). Technology types examined include:

•     Solubility & Bioavailability
•     Targeted Delivery
•     Drug Nanocrystals
•     Total Nanocarriers
•     Liposomes
•     Carbon nanotubes
•     Gold Nanocarriers
•     Dendrimers
•     Micelles
•     Polymer-based Nanocarriers
•     Nanoshells
•     Ceramic Nanocarriers
•     Calcium phosphate Nanocarriers

The forecast for nanotech drug delivery to 2021  shows that the total addressable market  will reach US$ 136,134 million by 2021 and the compound annual growth rate (CAGR) is estimated to be 49.96% over the period 2010-2021.

Also included in the report is:

• An overview of nanotechnology;
• Identification of several key drivers for nanotechnology adoption in medicine and biomedicine;
• The most important fields for the adoption of nanotechnology in medicine; and
• An explanation of how nanotechnology is already having an impact on the drugs delivery sector through several relevant case studies.

In addition to an examination of general trends, Nanotechnology in Drug Delivery 2011 identifies five current & future challenges to as well as the major barriers to adoption of nanotechnology in medicine and biomedicine and provides a Technology Adoption Roadmap.

The report examines the stage of development of key nanotechnologies used in drug delivery, sorted by applications, including

• Nanopharmaceuticals
• Nanobiotechnology in drug delivery
• Analytical techniques for nanoparticle drug delivery
• Clinically approved nanocarrier-based formulations present on the market and in the pipeline
• Clinically approved nanocrystals-based formulations present on the market and in development
• Nanotechnology-based alternatives to nanocarriers in drug delivery
• Present and future applications

TABLE OF CONTENTS

Executive Summary

Chapter 1.
Introduction and Methodology

Report Scope
      Thematic Scope
      Scope of Data Analysis
      Temporal Scope of Analysis
      Geographical Scope

Report objective

Methodology
     Cientifica, Ltd Nanotechnology Model
     Major Assumptions
     Market Values And Publishing Activity
     Publishing Activity And TAM (2000-2010 period)
     Calculation of CAGR
     The Nanoscale


Chapter 2.
Introduction to Nanotechnology & Medicine

Overview of nanotechnology

      Why is Nanotechnology A Critical Application for Medicine and Biomedicine?

      Why Nanotechnology Is Needed for Medicine and Biomedicine?



What are the Key Drivers for Adoption of Nanotechnology in Medicine and
Biomedicine?

      Drivers For Nanoparticle Drug Delivery
                        THE AIM OF DRUG TARGETING
                    
                        REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING
                    
                        MARKET DRIVERS FOR ENHANCED DRUG DELIVERY
                    
      Increasing Proportion of The Aging Population
      Demand More Affordable Health Care
      Public Health ­ Ending disease
      Demand for More Innovation
      Social responsibility


The Most Important Fields in The Adoption of Nanotechnology in Medicine and
Biomedicine

      Nanotechnology in Drug Delivery
      Nanotechnology in Medical and Biomedical Diagnostics
      Nanotechnology in Regenerative Medicine and Tissue Engineering
      Other Applications For Nanomaterials In The Medical And Pharmaceutical Sector


How Nanotechnology is Already Having an Impact on The Drug Delivery Sector

      Case Study 1 ­ Magnetic Field Acts as "Remote Control" to Deliver Nanomedicine

      Case Study 2 - Adaptive Micro and Nanoparticles: Temporal Control Over Carrier
      Properties to Facilitate Drug Delivery

      Case Study 3 ­ Fabrication of a Nanocarrier System Through Self-Assembly of
      Plasma Protein And Its Tumour Targeting

      Case Study 4 ­ IBM And The Institute of Bioengineering and Nanotechnology
      Find Breakthrough For MRSA Treatment - New Molecular Structures Could Fight
      Infectious Diseases Better Than Conventional Antibiotics


References

Chapter 3.
Key Barriers to The Adoption of Nanotechnology in Medicine and Biomedicine

      Nanotoxicity Nanopollution and Nanosafety
      Ethical considerations of nanotherapies
      Delayed Nanoregulation

Current & Future Challenges of The Adoption of Nanotechnology in Medicine and
Biomedicine
      Current & Future Challenges of Nanosafety And Risk Management
      Current & Future Challenges of Nanoregulation
      Current & Future Challenges of Nanomedicine Industry
      Current & Future Challenges of Sustained Innovation
      Current & Future Challenges of Cooperation
Market Analysis (2000-2010) Without Segmentation

Market Forecast to 2021 Without Segmentation


References

Chapter 4:
Nanotechnology in Drug Delivery

Overview of The Key Nanotechnologies Used in Drug Delivery Sorted by

Applications
      Nanopharmaceuticals
      Nanotechnology In Drug Delivery
      Nanobiotechnology In Drug Delivery

      Analytical Techniques For Nanoparticle Drug Delivery
                     PROPERTIES
                
                     PRODUCTION OF NANOPARTICLES
                
                     MEASURING DISPERSION OF NANOPARTICLES
                
                     ANALYSIS OF CARRIER SYSTEMS
                

      Nanocarriers
                     CLASSIFICATION OF NANOCARRIERS
                
                     MULTIFUNCTIONAL NANOCARRIERS - DRUG DELIVERY AND
                
                     MEDICAL/BIOMEDICAL DIAGNOSTICS
                     NANOCARRIERS AS DRUG CARRIERS
                
                     WHAT CAN NANOPARTICLES DO IN DRUG DELIVERY?
                
                     POLYMER-BASED NANOCARRIERS (POLYMERIC NANOPARTICLES)
                
                     LIPID-BASED NANOCARRIERS
                
                     ORGANIC NANOCARRIERS
                
                     INORGANIC NANOCARRIERS
                
                     DISADVANTAGES ASSOCIATED WITH NANOCARRIERS
                

      Nanotechnology-Based Alternatives to Nanocarriers in Drug Delivery
                 DRUG NANOCRYSTALS: NANOSIZING THE DRUGS

      The Most Relevant Key Technologies in The Key Area of Nanotechnology in Drug
      Delivery

Stage of Development of Key Nanotechnologies Used in Drug Delivery

      Clinically Approved Nanocarrier-Based Formulations With Presence in The Market
                     THE FIRST NANOPARTICLE DRUG DELIVERY SYSTEM REACHES THE
                
                     MARKET

      Clinically Approved Nanocrystals-Based Formulations With Presence in the Market
      Present And Future Applications
      Market Analysis With Segmentation
                    MARKET BY COUNTRY (2000-2010)
                
                    MARKET BY KEY TECHNOLOGY (2000-2010)
                

Technology Adoption Roadmap

      Projected Product Pipeline For Nanocarrier-Based Drug Formulations In Drug
      Delivery Market
                    OVERVIEW OF NANOPARTICLE DRUG DELIVERY SYSTEM (DDS) IN
                
                    VARIOUS APPLICATIONS
                    AVAILABLE APPLICATIONS OF NANOPARTCILE IN DRUG DELIVERY
                

      Projected Product Pipeline For Nanocrystals-Based Drug Formulations In Drug
      Delivery Market;
                    SEMAPIMOD® (CYTOKINE, PHARMASCIENCES)
                
                    PAXCEEDTM
                
                    THERALUXTM
                
                    NUCRYST®
                

      Market Forecast to 2021, With Segmentation
                    MARKET FORECAST BY COUNTRY BY 2021
                
                    MARKET FORECAST BY KEY TECHNOLOGY BY 2021
                

      SWOT Analysis (2011-2021 period)


References

Table of Exhibits

Chapter One. Introduction and Methodology

Exhibit 1.1
Formula for the calculation of the Compound Annual Growth Rate (CAGR), (top).
Formula for the calculation of the Compound Annual Growth Rate (CAGR) in this report,
for the 2011-2021 period, (bottom) [2].

Exhibit 1.2
Formula for the verification of the calculated values of the Compound Annual Growth
Rate (CAGR), (top).
Formula for the verification of the calculated values of the Compound Annual Growth
Rate (CAGR) in this report, for the 2011-2021 period, (bottom) [2].

Exhibit 1.3
The equivalence between 1 nm in meter (top). The equivalence between 1 meter in
nanometre (bottom).


Chapter Two: Introduction to Nanotechnology & Medicine

Exhibit 2.1
Illustration of the fact that the periodic table of elements, as we know it (at meter scale)
governed by classic Newtonian laws of physics. However, when perceived at nanoscale,
those elements are governed by the laws of quantum physics.

Exhibit 2.2
Proportion of the population aged over 65 and over 80 [7].

Exhibit 2.3
Illustration of a diagram of each property of nanocarriers (size, shape, surface chemistry
and mechanical properties) and their parameters subjected to optimization in order to
improve their efficiency [10].


Chapter Three: Technology Adoption Roadmap

Exhibit 3.1
Specified expected barriers in the development of particular types of nanoparticles
(Courtesy of CienNanoroadmap Synthesis Report), [6].

Exhibit 3.2
Illustration of the measures adoption roadmap to combat/attenuate the key barriers to the
adoption of nanotechnology in medicine and biomedicine (Source: Cientifica, Ltd.).

Exhibit 3.3
Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology
in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
Exhibit 3.4
Line chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology
in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).

Exhibit 3.5
Bar chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology in
drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).

Exhibit 3.6
Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-
2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica
(all figures US$ Million Dollars).

Exhibit 3.7
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, without segmentation, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 3.8
Bar chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-
2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica
(all figures US$ Million Dollars).

Chapter Four: Nanotechnology in Drug Delivery

Exhibit 4.1
Typical Image of Colloidal Gold Nanoparticles [1].

Exhibit 4.2
Examples of nanocarriers used for targeting cancer. (A) A whole range of delivery agents
are possible but the main components typically include a nanocarrier, a targeting moiety
conjugated to the nanocarrier and a cargo (such as the desired chemotherapeutic drugs); (B)
Schematic diagram of the drug conjugation and entrapment processes. The
chemotherapeutics could be bound to the nanocarrier, as in the use of polymer - drug
conjugates, dendrimers and some particulate carriers or they could be entrapped inside the
nanocarrier [3].

Exhibit 4.3
Schematic representation of different mechanisms of drug delivery to tumours using
nanocarriers. Polymeric nanoparticles are shown as representative nanocarriers (circles).
Passive tissue targeting is achieved by extravasation of nanoparticles through increased
permeability of the tumour vasculature and ineffective lymphatic drainage (EPR effect).
Active cellular targeting (inset) can be achieved by functionalizing the surface of
nanocarriers with ligands that induce cell-specific recognition and binding. The
nanocarriers can (a) release their contents in close proximity to the target tumour cells; (b)
attach to the membrane of the tumour cell and play the role of an extracellular sustained-
release drug depot; or (c) internalize into the tumour cell [3].

Exhibit 4.4
Advantages and disadvantages of different methods for the production of drug
nanocrystals [6].
Exhibit 4.5
Representative examples of clinically approved nanocarrier-based drug formulations with
presence on the market [4].

Exhibit 4.6
Some examples of nano-based platforms and their current stage of development for use in
cancer therapy [3].

Exhibit 4.7
Representative examples of clinically approved nanocrystals-based drug formulations with
presence on the market [6]

Exhibit 4.8
Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology
in drug delivery, all countries studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.9
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all
figures in percentage).

Exhibit 4.10
Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.11
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.12
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010), for nanotechnology in drug delivery, by world regions and countries, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.13
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.14
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, all world regions and countries studied, source: Cientifica
(all figures in percentage).

Exhibit 4.15
Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, all world regions and countries studied, source: Cientifica
(all figures US$ Million Dollars).
Exhibit 4.16
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
figures in percentage).

Exhibit 4.17
Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.18
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.19
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010), for nanotechnology in drug delivery, European Union countries studied, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.20
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.21
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures in
percentage).

Exhibit 4.22
Horizontal bar graph representing the Total Addressable Market, TAM In 2010, for
nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.23
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.24
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.25
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$
Million Dollars).
Exhibit 4.26
Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology
in drug delivery, all most relevant key technologies, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.27
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
in percentage).

Exhibit 4.28
Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.29
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.30
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010) , for nanotechnology in drug delivery, all key technologies studied, source: Cientifica
(all figures US$ Million Dollars).

Exhibit 4.31
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for
nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.32
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in
percentage).

Exhibit 4.33
Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.34
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.35
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010) , for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all
figures US$ Million Dollars).
Exhibit 4.36
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.37
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica
(all figures in percentage).

Exhibit 4.38
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica
(all figures US$ Million Dollars).

Exhibit 4.39
3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000-
2010) , for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.40
3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for
nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica
(all figures US$ Million Dollars).

Exhibit 4.41
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source:
Cientifica (all figures in percentage).

Exhibit 4.42
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.43
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures
in percentage).

Exhibit 4.44
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.45
In vivo effects of nanocrystals-based drug formulations [6].
Exhibit 4.46
Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-
2021 period), for nanotechnology in drug delivery, by world regions / countries, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.47
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, by world regions, source: Cientifica (all figures in
percentage).

Exhibit 4.48
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures US$
Million Dollars).

Exhibit 4.49
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, by world regions, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.50
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by world regions,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.51
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, by world regions, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.52
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica
(all figures in percentage).

Exhibit 4.53
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, by all world regions / countries studied, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.54
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, by all world regions / countries
studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.55
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by all world
regions / countries studied, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.56
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, by all world regions /
countries studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.57
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
figures in percentage).

Exhibit 4.58
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, European Union countries studied, source: Cientifica
(all figures US$ Million Dollars).

Exhibit 4.59
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, European Union countries
studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.60
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, European Union
countries studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.61
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, European Union
countries studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.62
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures in
percentage).

Exhibit 4.63
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.64
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, Asian countries studied, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.65
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, Asian countries
studied, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.66
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, Asian countries studied,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.67
Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-
2021 period), for nanotechnology in drug delivery, all most relevant key technologies,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.68
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
in percentage).

Exhibit 4.69
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all
figures in percentage).

Exhibit 4.70
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, all key technologies studied,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.71
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key
technologies studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.72
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies
studied, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.73
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in
percentage).

Exhibit 4.74
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures
US$ Million Dollars).

Exhibit 4.75
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source:
Cientifica (all figures US$ Million Dollars).
Exhibit 4.76
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a
whole, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.77
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.78
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica
(all figures in percentage).

Exhibit 4.79
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source:
Cientifica (all figures US$ Million Dollars).

Exhibit 4.80
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus drug
nanocrystals, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.81
3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast
by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus
drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.82
3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus drug
nanocrystals, source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.83
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source:
Cientifica (all figures in percentage).

Exhibit 4.84
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.85
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, impact of drug solubility and drug
bioavailability, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.86
3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for
nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures
in percentage).

Exhibit 4.87
Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021,
for nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all
figures US$ Million Dollars).

Exhibit 4.88
Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the
2011-2021 period), for nanotechnology in drug delivery, impact of targeted delivery,
source: Cientifica (all figures US$ Million Dollars).

Exhibit 4.89
SWOT analysis to evaluate the strengths, weaknesses, opportunities and threats involved in
nanotechnology in drug delivery In the scope of the technology adoption roadmap (during
the 2011-2021 period).



Appendix

Exhibit A.1
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: North America; country: USA.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.2
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: European Union; country: Germany.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.3
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: European Union; country: France.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.4
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: European Union; country: UK.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.
Exhibit A.5
Table of the organizations with publishing activity in PubMed periodicals (2000-2010),
based on PubMed, for Nanotechnology in Drug Delivery. Country: Russian Federation.
Organizations are ordered alphabetically (increasing order).

Exhibit A.6
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: Asia; country: India.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.7
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: Asia; country: India.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.8
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: Asia; country: Japan.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.9
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: Asia; country: P R China.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.10
Table of the top 20 organizations showing the highest publishing activity in PubMed
periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World
Region: Asia; country: South Korea (Republic of Korea).
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.

Exhibit A.11
Table of the organizations with publishing activity in PubMed periodicals (2000-2010),
based on PubMed, for Nanotechnology in Drug Delivery. Asia; country: Taiwan.
Organizations are ordered first by descending order of total articles published and then
ordered alphabetically (increasing order), if applicable.